Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2005

View Archived Issues

Seattle Genetics discontinues development of SGN-15

YC-1 inhibits mesangial cell proliferation through suppression of cyclin D1

Mechanisms underlying NSC-686288 antineoplastic activity

Specific MMP-9 inhibitor reduces infarct volume in mice

HCT-1026 reduces bone resorption in female patients with osteopenia

StaphVAX vaccine shows promise in the prevention of postsurgical S. aureus infections

Fast track status for XTL-6865 in prevention of posttransplant HCV reinfection

Avelox approved in Europe for cSSSI

Geron and Merck & Co. collaborate on cancer vaccine targeting telomerase

Xanodyne given go-ahead to acquire aaiPharma assets

Orphan drug designation for CTCE-9908 for treatment of osteogenic sarcoma

OGX-011 begins phase II study for high-risk prostate cancer

Roche files for European approval of Tamiflu for pediatric flu prevention

Sosei to acquire Arakis

Gamma-secretase inhibitors tested for cancer treatment

BDSI secures financing for BEMA-fentanyl trials

Influvac for influenza prevention receives Canadian approval

Novel analgesic agents claimed in recent patent literature

Improved endothelial function maintained with S-18886 in atherosclerosis

Novel agents for premature ejaculation in development at Pfizer

Novel agents imparted for asthma and other inflammatory and allergic disorders

Natalizumab reported to improve the effects of interferon beta-1a in multiple sclerosis

Update on the effects of neramexane in Alzheimer's disease

Zileuton shows efficacy in the treatment of inflammatory facial acne

Vical begins phase I study of gene-based IL-2 with electroporation

Colostrinin prevents beta-amyloid fibril formation and protects neuroblastoma cells in vitro

Calcitonin gene-related peptide receptor antagonist has therapeutic potential in headache

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...